1. Home
  2. PLSE vs GENB Comparison

PLSE vs GENB Comparison

Compare PLSE & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$29.84

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$17.92

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PLSE
GENB
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PLSE
GENB
Price
$29.84
$17.92
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$22.00
$23.20
AVG Volume (30 Days)
357.5K
1.1M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
N/A
Revenue Next Year
$287.54
$16.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$11.00
52 Week High
$31.00
$17.42

Technical Indicators

Market Signals
Indicator
PLSE
GENB
Relative Strength Index (RSI) 65.89 68.74
Support Level $23.94 $11.73
Resistance Level N/A N/A
Average True Range (ATR) 1.99 1.07
MACD 0.26 0.42
Stochastic Oscillator 76.07 94.70

Price Performance

Historical Comparison
PLSE
GENB

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: